Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

Artículo original

Año: 2022

Ruiz-Villaverde, R; Fernandez-Freire, LR; Font-Ugalde, P; Galan-Gutierrez, M

Título: JOURNAL OF CLINICAL MEDICINE

• Q2